Published in HIV AIDS (Auckl) on June 28, 2011
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis (2015) 1.76
Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis (2015) 0.95
Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis. Biochem Biophys Res Commun (2015) 0.76
Recovery of Bone Mineral Density Following Discontinuation of Tenofovir-Based HIV Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr (2017) 0.75
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med (1997) 6.88
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med (1995) 2.58
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS (2001) 2.17
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (2009) 2.08
Continuous antiretroviral therapy decreases bone mineral density. AIDS (2009) 1.96
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. J Clin Endocrinol Metab (2006) 1.87
Tenofovir-associated renal and bone toxicity. HIV Med (2009) 1.82
The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med (2005) 1.80
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read (2007) 1.53
Metabolic bone disease in HIV infection. AIDS (2009) 1.36
Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab (2004) 1.32
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.31
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS (2009) 1.27
Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS (2001) 1.21
Potential predictive factors of osteoporosis in HIV-positive subjects. Bone (2005) 1.12
Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab (1998) 1.09
Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol (2009) 1.06
Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS (2001) 1.03
Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J Orthop Res (2002) 0.99
Open fractures of the tibia in HIV positive patients: a prospective controlled single-blind study. Injury (2004) 0.98
Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic) (2004) 0.91
Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab (2001) 0.91
Tenofovir-induced osteomalacia. Clin Exp Rheumatol (2010) 0.89
Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS (2001) 0.89
Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed (2005) 0.87
[Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir]. Rev Esp Med Nucl (2006) 0.85
Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine (2002) 0.84
Differences in bone mineral density and geometry in men and women: the Newcastle Thousand Families Study at 50 years old. Br J Radiol (2005) 0.83
Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience. J Assoc Physicians India (2008) 0.80
Osteoporosis and osteomalacia. Rheum Dis Clin North Am (2010) 0.79
Testosterone replacement therapy for bone loss prevention in HIV-infected males. Ann Pharmacother (2003) 0.78
Vertebral fractures in AIDS patients within 6 months from highly active antiretroviral therapy initiation: two case reports. AIDS (2008) 0.77
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis (2005) 1.88
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials (2007) 1.41
A review of the pharmacokinetics of abacavir. Clin Pharmacokinet (2008) 1.12
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. J Acquir Immune Defic Syndr (2006) 1.11
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS (2008) 1.07
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses (2002) 0.95
Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience. Adv Ther (2002) 0.91
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses (2012) 0.88
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. HIV Clin Trials (2006) 0.87
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. AIDS Res Hum Retroviruses (2010) 0.87
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 0.86
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clin Trials (2008) 0.86
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother (2009) 0.86
Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations. HIV Clin Trials (2007) 0.85
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses (2009) 0.83
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquir Immune Defic Syndr (2013) 0.83
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus. Pharmacotherapy (2004) 0.83
Atovaquone plus cholestyramine in patients coinfected with Babesia microti and Borrelia burgdorferi refractory to other treatment. Adv Ther (2006) 0.82
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis (2005) 0.80
Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). HIV Clin Trials (2009) 0.79
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antivir Ther (2007) 0.78
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. BMC Infect Dis (2005) 0.78
Mistaken conclusions in a nonmelanoma skin cancer article published in JAMA. Dermatol Surg (2014) 0.78
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infect Dis (2003) 0.78
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population. HIV AIDS (Auckl) (2011) 0.75